FDA Appoints Biotech Veteran George Tidmarsh to Lead Drug Regulation Center Amid Agency Restructuring
核心洞察
The FDA has appointed Dr. George Tidmarsh, a former pharmaceutical executive and cancer specialist, to direct the Center for Drug Evaluation and Research (搜索), the agency's largest division responsible for reviewing drug safety and effectiveness.
Tidmarsh brings extensive industry experience, having founded multiple pharmaceutical companies including Horizon Pharmaceuticals (搜索) and developed seven FDA-approved drugs, providing stability during significant agency upheaval.
The appointment comes as the FDA faces major workforce reductions with about 2,000 staff layoffs and over 1,000 departures through buyouts or early retirement under Health Secretary Robert F. Kennedy Jr.'s restructuring efforts.
The Food and Drug Administration announced Monday the appointment of Dr. George Tidmarsh, a veteran pharmaceutical executive and cancer specialist, to lead the Center for Drug Evaluation and Research (搜索) (CDER), the agency's largest and most critical division. The appointment addresses a leadership vacuum that has persisted since January and comes amid unprecedented workforce reductions across the federal health agency.
Industry Veteran Takes Helm of Critical FDA Division
Tidmarsh, who currently serves as an adjunct professor of pediatrics and neonatology at Stanford University's School of Medicine, will oversee nearly 6,000 staffers responsible for reviewing the safety and effectiveness of new drugs and monitoring existing treatments. CDER regulates over-the-counter and prescription medications, including biologic therapies and generics, making it one of the most influential regulatory bodies in global healthcare.
"Dr. Tidmarsh is an accomplished physician-scientist and leader whose experience spans the full arc of drug development—from bench to bedside," said FDA Commissioner Dr. Marty Makary in a statement. "His appointment to lead CDER brings exceptional scientific, regulatory, and operational expertise to the agency."
The position has remained vacant since Dr. Patrizia Cavazzoni stepped down in January, just days before President Donald Trump took office. Acting head Jacqueline Corrigan-Curay announced her retirement in June, leaving the critical division without permanent leadership during a period of significant regulatory challenges.
Extensive Pharmaceutical Background
Tidmarsh brings substantial industry experience to the role, having founded and led several pharmaceutical companies throughout his career. He served as CEO of La Jolla Pharmaceuticals (搜索) and founded Horizon Pharmaceuticals (搜索), which was later acquired by Amgen for $28 billion. He also established Threshold Pharmaceutical (搜索) and held senior positions at other biotech companies.
His involvement in drug development extends to seven now-approved treatments, providing him with firsthand experience in navigating the regulatory process he will now oversee. This background is viewed as potentially reassuring to the pharmaceutical industry, which has faced uncertainty amid broader changes at the FDA.
Critical Voice on Regulatory Decisions
Despite his industry ties, Tidmarsh has demonstrated willingness to critique FDA regulatory decisions. In an April opinion piece, he criticized key decisions made by Dr. Peter Marks, the former vaccine chief who was forced out in March under the Kennedy administration. Specifically, Tidmarsh opposed the accelerated approval of Biogen's controversial Alzheimer's drug Aduhelm and questioned the decision to expand approval of Sarepta Therapeutics' Duchenne muscular dystrophy (搜索) treatment Elevidys.
The Elevidys controversy has intensified recently, with the FDA last week asking Sarepta Therapeutics to halt all shipments after three patients died from liver failure (搜索) following treatment. The company has refused to completely stop shipments, continuing to provide the therapy to patients with the condition who can still walk, citing data showing "no new or changed safety signals" within that group.
Agency Under Pressure
Tidmarsh assumes leadership during a period of unprecedented upheaval at the FDA. Under Health Secretary Robert F. Kennedy Jr.'s oversight, approximately 2,000 FDA staffers have been laid off as part of widespread cuts to the federal health workforce. More than 1,000 additional employees have taken buyouts or early retirement, while many others are reportedly seeking new positions.
These departures have raised concerns about the FDA's ability to maintain basic operations, including the timely review of new drug applications. The workforce reductions come as the agency faces pressure to review the safety of established treatments, including the abortion pill mifepristone, certain antidepressants, and hormone-replacement drugs for menopause.
Leadership Transformation
The appointment represents the latest in a series of leadership changes across the FDA's senior ranks. Nearly all top positions have experienced turnover in recent months due to retirements, resignations, or administrative actions by the current administration.
In May, Dr. Vinay Prasad, a prominent critic of the FDA's COVID response, was named to run the agency's vaccine center and serve as chief medical officer, replacing the ousted Marks. The head of the FDA's tobacco center was also forced to step down in April, with no permanent replacement yet announced.
As Tidmarsh takes on his new role, he will be responsible for implementing the regulatory agenda outlined by Commissioner Makary and Secretary Kennedy, while maintaining the scientific rigor expected in drug evaluation and approval processes. His extensive industry experience and willingness to challenge previous regulatory decisions suggest he may bring a more stringent approach to drug oversight, particularly regarding accelerated approval pathways and prescription drug advertising practices.